Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
- Andover, MA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be at least 18 years of age;
- Provide written informed consent;
- Have a subject reported history of dry eye for at least 6 months
- Have a history of use or desire to use eye drops for dry eye symptoms within 6 months
Exclusion Criteria:
- Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
- Have ab uncontrolled systemic disease:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: RGN-259
RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
|
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Other Names:
|
|
Placebo Comparator: Placebo
It is composed of the same excipients as RGN-259 but does not contain Tβ4
|
It is composed of the same excipients as RGN-259 but does not contain Tβ4
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ocular Discomfort
Time Frame: 29 days after first dosing
|
Change from Baseline at Day 29 using the Ora Calibra® Ocular Discomfort Scale (6-point scale where 0 = none and 5 = worst)
|
29 days after first dosing
|
|
Corneal Fluorescein Staining
Time Frame: 29 days after first dosing
|
Change from Baseline at Day 29 using the Ora Calibra® scale (5-point scale with half (0.5) increments where 0 = none and 4 = severe)
|
29 days after first dosing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Corneal Fluorescein Staining
Time Frame: 8, 15, 29 days after first dosing
|
Comparing each of active group & Placebo.
|
8, 15, 29 days after first dosing
|
|
Unanesthetized Schirmer's Test
Time Frame: 29 days after first dosing
|
Comparing each of active group & Placebo.
|
29 days after first dosing
|
|
Ocular Surface Disease Index (OSDI)©
Time Frame: 8, 15, 29 days after first dosing
|
Comparing each of active group & Placebo.
|
8, 15, 29 days after first dosing
|
|
Tear Film Break-Up Time
Time Frame: 8, 15, 29 days after first dosing
|
Comparing each of active group & Placebo.
|
8, 15, 29 days after first dosing
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Acuity
Time Frame: 1, 8, 15, 29 days
|
Change or shifts from Baseline
|
1, 8, 15, 29 days
|
|
Change in Biomicroscopy Using the Slit-lamp
Time Frame: 1, 8, 15, 29 days
|
Change or shifts from Baseline
|
1, 8, 15, 29 days
|
|
Adverse Event Query
Time Frame: 1, 8, 15, 29 days
|
Frequencies
|
1, 8, 15, 29 days
|
|
Change in Biomicroscopy Using the Undilated Fundoscopy
Time Frame: 1, 29 days
|
Change or shifts from Baseline
|
1, 29 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RGN-259/16-110-0008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.